Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here are three small-cap stocks to avoid and some other investments you should consider instead.
Quanex (NX)
Market Cap: $862.4 million
Starting in the seamless tube industry, Quanex (NYSE: NX) manufactures building products like window, door, kitchen, and bath cabinet components.
Why Do We Pass on NX?
- Projected sales are flat for the next 12 months, implying demand will slow from its two-year trend
- Incremental sales over the last two years were much less profitable as its earnings per share fell by 14.1% annually while its revenue grew
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Quanex is trading at $19.02 per share, or 9.9x forward P/E. To fully understand why you should be careful with NX, check out our full research report (it’s free).
Integra LifeSciences (IART)
Market Cap: $986.2 million
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Is IART Risky?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Earnings per share fell by 4.6% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
- 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
At $12.85 per share, Integra LifeSciences trades at 6.4x forward P/E. Check out our free in-depth research report to learn more about why IART doesn’t pass our bar.
Enovis (ENOV)
Market Cap: $1.02 billion
With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE: ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.
Why Do We Avoid ENOV?
- Sales stagnated over the last five years and signal the need for new growth strategies
- Earnings per share fell by 9.5% annually over the last five years while its revenue was flat, showing each sale was less profitable
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Enovis’s stock price of $17.75 implies a valuation ratio of 5x forward P/E. If you’re considering ENOV for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
